AstraZeneca Plc’s Greatest Strengths

Two standout factors supporting an investment in AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When I think of pharmaceutical company AstraZeneca (LSE: AZN) (NYSE: AZN.US), two factors jump out at me as the firm’s greatest strengths and top the list of what makes the company  attractive as an investment proposition.

1) Promising product development pipeline

AstraZeneca’s turnover and profits have dwindled in recent years thanks to increased competition after some the firm’s bestselling drugs emerged from periods of patent protection. However, the firm is building up an exciting pipeline of new products, each a potential blockbuster, and forward-looking investors are driving the share price higher in anticipation of better times ahead.

astrazenecaThe path from test tube to medicine cabinet is long, torturous, time-consuming and expensive. Something like one or two compounds in 10,000 tested end up as licensed treatments. Scientists carry out testing along the way in phases in order to comply with regulation, but phase three is the step before licensing, so when a formulation is approaching phase three testing, investors tend to get excited. However, there’s many a slip between cup and lip, leading to some potential treatments getting the chop even at that stage after, perhaps, many years of development activity.

Right now, AstraZeneca reckons it has 11 new molecular entities in Phase III or registration; almost double compared with last year. There are also 19 candidates for potential new Phase III starts in 2014-15. Such late-stage development activity is a key factor in achieving a return to revenue and earnings’ growth.

2) Firm cash flow

Although revenue and profits are struggling, cash flow is holding up quite well:

Year to December 2009 2010 2011 2012 2013
Revenue ($m) 32,804 33,269 33,591 27,973 25,711
Net cash from   operations ($m) 11,739 10,680 7,821 6,948 7,400
Adjusted earnings   per share (cents) 632 671 728 641 505

A strong cash flow performance seems to provide support for the share price. As long as AstraZeneca generates cash, it can keep recycling funds into R&D and pay dividends to investors. Cash flow is an important figure to watch while we wait for new products to boost revenue and profits.

What now?

Right now AstraZeneca seems to attract mainly as a turnaround proposition. It’s conceivable that a return to growth could occur as new products take off.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin does not own shares in AstraZeneca.

More on Investing Articles

White female supervisor working at an oil rig
Investing Articles

Could the UK general election be bad news for this FTSE 250 energy producer?

The country is due to vote in the general election on 4 July. Our writer looks at the possible implications…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should we buy cheap FTSE 100 shares now, before it’s too late?

The FTSE 100 is up 5% so far in 2024 and hit an all-time high in May. That means the…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Here’s why I think the Lloyds share price could hit a 5-year high in 2024

It's up 13.5% so far in 2024, and reaching new highs. But where might the Lloyds Bank share price go…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

If I’d put £15k into this FTSE 250 stock in 2008, I’d have over £1.26m today

This multi-billion-pound business has created plenty of millionaires over the last 16 years, but can it repeat this performance?

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

3 dividend shares I’ve bought for the next decade!

I think these UK dividend shares can amplify my long-term passive income, and could even be on track to becoming…

Read more »

Investing Articles

If I’d put £5,000 in Scottish Mortgage shares at the start of 2024, here’s what I’d have now

Scottish Mortgage shares have staged a recovery lately, powered by the public and private growth stocks held in the portfolio.

Read more »

Happy couple showing relief at news
Investing Articles

9.9% dividend yield! Is this FTSE 100 stock a brilliant bargain?

This leading British enterprise looks like a delicious deal for passive income, trading at a low multiple while offering a…

Read more »

Investing Articles

If I’d put £5k in a FTSE 100 tracker fund 5 years ago, here’s what I’d have now

Investing in a FTSE 100 index fund is a terrific way to start building wealth passively with minimum effort. But…

Read more »